

Neuralstem, Inc.
Form 8-K
January 08, 2007

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): January 4, 2007

Neuralstem, Inc.
(Exact name of registrant as specified in Charter)

**Delaware
(State or other
jurisdiction of
incorporation or
organization)**

**000-1357459
(Commission File No.)**

**52-2007292
(IRS Employee
Identification No.)**

**9700 Great Seneca Highway, Rockville, Maryland 20850
(Address of Principal Executive Offices)**

**(301) 366-4841
(Issuer Telephone number)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On January 4, 2007, Neuralstem, Inc. issued a press release announcing that the European Patent Office intends to grant the company's European Patent Application No. 97923569.4 which is titled "Isolation, Propagation and Directed Differentiation of Stem Cells from Embryonic and Adult Central Nervous System of Mammals."

A copy of that press release is attached to this report as Exhibit 99.1.

Item 9.01 Financial Statement and Exhibits.

Exhibit

Number

Description

99.1	Press Release Dated January 4, 2007
------	-------------------------------------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC.

By: /s/ I. Richard Garr

I. Richard Garr
Chief Executive Officer

Dated: January 7, 2007
